135 results about "Vancomycinum" patented technology

The invention provides a novel enterococcus strain Enterococcus qinghaiensis SCFF543 and an anti-oxidation application of the novel enterococcus strain Enterococcus qinghaiensis SCFF543, and belongs to the technical field of microorganisms. Wherein the strain is preserved in the China General Microbiological Culture Collection Center (CGMCC) on June 10, 2025, and the preservation number is CGMCC No.34843. The invention further discloses a preparation method of the strain. The strain is separated from homemade casein of herdsman families in Demaoha City in Haixi, Qinghai province, has the advantages of strong antioxidant capacity, no vancomycin resistance, strong adhesiveness and the like, and can be suitable for preparing probiotic products with antioxidant effects.

The present invention belongs to the field of biotechnology, and specifically relates to the use of the CD630_27900 gene in reducing the tolerance of Clostridium difficile. Knocking out the CD630_27900 gene can reduce the tolerance of Clostridium difficile to acidic environments and antibiotics and reduce its cytotoxicity; the sequence of the CD630_27900 gene is shown in SEQ ID NO.1; the antibiotics include ampicillin, metronidazole, amoxicillin, vancomycin, norfloxacin, cefoxitin, clindamycin and kanamycin. The research results of the present invention suggest that the CD630_27900 gene can be used as a target for inhibiting the drug resistance and reducing the toxicity of Clostridium difficile, providing a new idea for the treatment of Clostridium difficile infection (CDI).

The invention discloses a microneedle patch loaded with vancomycin and a gold / zinc cerium composite nanomaterial and application of the microneedle patch in abscess wound treatment, the microneedle patch comprises a backing layer and a needle body array arranged on the backing layer, the backing layer and the needle body array are formed by an aqueous solution of a degradable polymer, vancomycin and a gold / zinc cerium composite nano material are loaded in an aqueous solution of the degradable polymer for forming the needle body array. According to the microneedle patch disclosed by the invention, based on the photo-thermal synergistic effect of the antibiotics and the gold / zinc-cerium composite nanomaterial, rapid healing of abscess wounds is realized from the aspects of inhibiting growth of bacteria, relieving oxidative stress, promoting angiogenesis and the like.

The invention provides a vancomycin clearance rate prediction method and device based on deep learning, and relates to the technical field of data processing, and the method comprises the steps: obtaining multi-dimensional feature information of a target dimension of a to-be-evaluated user, the data source of the multi-dimensional feature information comprises at least one of human body sign information, current hospitalization and operation information and current blood biochemical test information; the target dimension is obtained by applying a vancomycin clearance rate as a target variable and multi-dimensional feature information corresponding to a plurality of vancomycin medication users as covariables to a gradient boosting decision tree model; inputting the multi-dimensional feature information of the target dimension of the user to be evaluated into the vancomycin clearance rate prediction model based on the TabPFN to obtain a vancomycin clearance rate prediction result of the user to be evaluated; according to the method, multiple factors influencing drug removal can be more comprehensively considered, and the prediction accuracy and individuation degree are improved.

Compositions comprising 5. salivarius strain SALI-10 and / or salivarius 10 peptide are taught. Also taught are methods of treating bacterial infections comprising administering a pharmaceutically acceptable amount of the composition to the patient with a bacterial infection caused by a pathogen from, for example, multi-drug resistant (MDR) Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus dysagalactiae, vancomycin-resistant Enterococcus faecium, Porphyromonas gingivalis, Tannerella forsythia, and MDR Enterococcus faecalis.

The invention discloses a vancomycin antibacterial effect prediction method based on multivariate analysis, and relates to the technical field of medical data analysis and prediction.The vancomycin antibacterial effect prediction method comprises the steps that S1, prediction data of a target patient is collected, the prediction data comprises static baseline data acquired at the beginning of treatment and dynamic time sequence data acquired at a preset time interval in the treatment process; and S2, preprocessing the prediction data, wherein the preprocessing comprises performing data cleaning on missing values and abnormal values in the static baseline data and the dynamic time sequence data. According to the method, the static baseline data at the beginning of the treatment and the dynamic time sequence data in the treatment process are fused, and the time sequence evolution rule of the dynamic index is captured by using the long and short-term memory network, so that the treatment failure probability and the kidney injury risk probability are dynamically predicted. Meanwhile, supervised learning samples are generated through a sliding window, targeted data preprocessing and risk early warning and trend chart visualization are carried out, the prediction result can be updated in real time, and the prediction precision is improved.

The invention belongs to the technical field of nano-probes, and particularly relates to a nano-probe and a preparation method and application thereof.The nano-probe comprises a magnetic nano-material and a long afterglow nano-material, the magnetic nano-material comprises magnetic nano-particles modified with concanavalin A and is used for recognizing, capturing and separating bacteria, and the long afterglow nano-material is a long afterglow nano-material. The long-afterglow nano-material comprises green long-afterglow nano-particles of which the surfaces are modified with polymyxin B and red long-afterglow nano-particles of which the surfaces are modified with vancomycin, the green long-afterglow nanoparticles with the surfaces modified with polymyxin B and the red long-afterglow nanoparticles with the surfaces modified with vancomycin are respectively used for identifying anti-interference signal output, the nano-probe is applied to identification of gram-negative and positive bacteria, the anti-interference capability of detection can be improved, the whole process is rapid and simple, and the cost is low. And the cost is low, and the stability is high.

The invention discloses a culture medium for identifying gardnerella vaginalis, and relates to the technical field of bacterial culture media, the key points of the technical scheme are as follows: the culture medium comprises the following raw material components by concentration: 10.0 g / L of casein pancreatin digest, 3.0 g / L of cardiac pancreatin digest, 5.0 g / L of yeast extract powder, 1.0 g / L of corn starch, 5.0 g / L of sodium chloride and 13.0 g / L of agar, and the final concentration of defiberized sheep blood is 5%. The pharmaceutical composition is prepared from 1 mg / mL of sodium alginate, 1 mg / mL of sodium alginate, 1 mg / mL of polyanethole Sulfonate (SPS) and 10 [mu] g / mL of vancomycin. According to the invention, through optimal combination of specific components and dosages thereof, rapid identification and screening of gardnerella vaginalis can be realized, and the method has the advantages of accurate result, strong specificity and the like, and has practical popularization and application values.

This application relates to the field of tumor treatment technology, specifically to a drug combination and evaluation method for improving the sensitivity of MSS CRC to anti-PD-1 / PD-L1 therapy. The drug combination comprises vancomycin and an immune checkpoint inhibitor. Vancomycin is used to remodel the gut microbiota and reduce L-asparagine levels; the immune checkpoint inhibitor is used to activate CD8. + T-cell anti-tumor response. By combining vancomycin with immune checkpoint inhibitors, the antigen-presenting capacity of dendritic cells is enhanced, thereby increasing the sensitivity of MSS CRC to anti-PD-1 or anti-PD-L1 immunotherapy. This application focuses on the upstream initiation link of gut microbiota-metabolites-dendritic cells-immune activation, relieving the inhibition of dendritic cell antigen presentation by L-asparagine and enhancing CD8+. + T cell activation and tumor immune response enhance the sensitivity of MSS-type colorectal cancer to anti-PD-1 / PD-L1 therapy.

A dynamic antimicrobial hydrogel based on natural receptor-ligand recognition, and a preparation method and use thereof are provided. A ligand vancomycin and a receptor AA-based material each are first modified with a modification material, and then a photoinitiator is added to prepare a hydrogel material under irradiation of ultraviolet (UV) light. In the hydrogel, a three-dimensional (3D) network structure is formed through crosslinking. After undergoing a fracture under an external pressure, the hydrogel can rapidly heal itself through crosslinking due to a ligand-receptor interaction and a multi-hydrogen-bond interaction, which bio-mimicks a natural ligand-receptor interaction to realize the dynamics of the hydrogel material. The high antiomicrobial activity of vancomycin imparts the functionality of the hydrogel material; and the physiologically-derived monomer improves the biocompatibility and reduces the biological toxicity.

The invention discloses a blue fluorescent carbon dot as well as a preparation method and application thereof, and belongs to the technical field of drug monitoring. The carbon dot is a boron-nitrogen co-doped carbon dot, a carbon source is citric acid, a nitrogen source is p-phenylenediamine, and a dopant is boric acid; wherein the mass ratio of the citric acid to the boric acid to the p-phenylenediamine is (10-13): (12-15): (11-14). The preparation method comprises the following steps: mixing citric acid, boric acid and p-phenylenediamine, adding ethanol, carrying out ultrasonic treatment, heating at 150-200 DEG C for 20-60 minutes, cooling to room temperature, and purifying and drying supernate to obtain the blue fluorescent carbon dots. The blue fluorescent carbon dot provided by the invention is simple in preparation method, easily available in raw materials and suitable for industrial production, and the prepared fluorescent carbon dot can be used for drug monitoring of vancomycin and is also suitable for detecting ofloxacin and / or levofloxacin in food.

A storage stable aqueous solution composition comprising vancomycin or a pharmaceutically acceptable salt thereof, at a concentration of 25-75 mg / mL; D-lactic acid or a pharmaceutically acceptable salt thereof; a cosolvent selected from propylene glycol and a mixture of propylene glycol and glycerol; and an inorganic salt containing a metal cation.

The present disclosure relates to a method of treating or preventing a preterm infant, the present invention relates to methods for intravenously administering a therapeutic amount of a composition comprising IGF-1 and IBGBP-3 in combination with a therapy selected from the group comprising caffeine, fentanyl, fluconazole, gentamicin, insulin, midazolam, morphine, a low dose of noradrenaline, vancomycin at a concentration of 5 mg / ml or less, parenteral nutrition (or a composition of the same use), and combinations thereof.

This invention discloses a method for isolating and extracting *Havnia vesicularis* using penicillin and vancomycin. The method mainly includes the following steps: inclusion and screening of patients with bipolar disorder; collection and processing of feces from these patients; isolation and treatment of *Havnia vesicularis* by adding penicillin and vancomycin to the feces; and identification of *Havnia vesicularis*. This invention improves the isolation efficiency and success rate of *Havnia vesicularis*, solving the problems of low isolation efficiency and poor identification accuracy in existing technologies.

The invention provides an anti-biofilm composition based on the synergistic effect of amino fullerene and vancomycin and application of the anti-biofilm composition. The mass ratio of the amino fullerene to the vancomycin is 10: 1. The amino fullerene derivative and vancomycin are combined to have a remarkable synergistic effect in the aspect of inhibiting the formation of the biological membrane for the first time, and the inhibition rate of the biological membrane reaches 93%, so that the amino fullerene derivative and vancomycin have a strong synergistic effect. The composition provided by the invention can effectively remove more than 40% of formed mature biological membranes (24-48-hour biological membranes), which is an effect which cannot be realized by independent use of vancomycin.

The invention discloses a preparation method of an RCA-Cas12a-DNA (deoxyribonucleic acid) tetrahedron sensor for detecting vancomycin in blood serum. The sensor comprises a target object vancomycin, a DNA chain TSP1, a DNA chain TSP2, a DNA chain TSP3 and a vancomycin aptamer Aptamer which are used for preparing a DNA tetrahedron, a DNA chain T, a DNA chain S, a T4 DNA ligase, exonuclease I and exonuclease III which are used for preparing circular DNA, a DNA chain P and phi29 DNA polymerase which are used for carrying out rolling circle amplification reaction, and LbCas12a nuclease, crRNA and ssDNA-FQ probes which are used for preparing a reporter. The aptamer is specifically combined with a target object, a non-nucleic acid target is converted into nucleic acid detection, and the application range of RCA and Cas12a is expanded; rCA is combined with Cas12a, so that a signal is amplified twice, the detection limit is lower, and the sensitivity is higher; compared with a traditional detection method, expensive instruments and equipment, complex and time-consuming sample pretreatment and skilled operators are not needed, and the method is more convenient and economical.

The present disclosure relates to a method of treatment or prophylaxis of a preterm infant by administering intravenously a therapeutic amount of a composition comprising IGF-1 and IBGBP-3 in combination with a therapy selected from the group comprising: caffeine, fentanyl, fluconazole, gentamicin, insulin, midazolam, morphine, low dose norepinephrine, vancomycin concentrations of 5 mg / ml or less, parenteral nutrition (or a composition for the same use) and combinations thereof.

The present invention discloses a fusion strain of Lactobacillus paracasei and Bifidobacterium adolescentis, as well as its preparation method and application, belonging to the field of strain breeding technology. A fusion strain of Lactobacillus paracasei and Bifidobacterium adolescentis was successfully prepared using the method provided by the present invention. The prepared fusion strain has a new morphology, a broadened carbon source utilization range, and significantly improved inhibitory effects on three pathogens. Furthermore, it is resistant to both vancomycin and mupirocin lithium salts. It also has good fermentation characteristics, with a pH of 4.05 and a titer of 114°T after 28 days of storage, and the viable cell count can still be maintained at 1×10 7 The protoplasts have a CFU / mL value of above 2260 mPa·s, a viscosity value of 37.462 g, a hardness of 37.462 g, and a consistency of 282.04 g·s, and can be used for the development and application of dairy products. The preparation method provided provides protoplasts with strong regeneration ability, high vitality, and high fusion rate, providing support for the selection of excellent lactic acid bacteria strains using protoplast fusion technology.

The invention discloses a method for performing gene editing in amycolatopsis orientalis. The method comprises the following steps: (1) constructing upstream and downstream homologous arm fragments nrps8-arm-A and nrps8-arm-Z of a target gene nrps8 sequence for DNA repair after knockout; (2) constructing a DNA (Deoxyribose Nucleic Acid) recombinant fragment gDNA-nrps8 capable of coding the sgRNA; (3) constructing a CRISPR (clustered regularly interspaced short palindromic repeats) / Cas9 editing plasmid pLYCS01; and (4) electrically transforming the pLYCS01 and the gDNA (deoxyribonucleic acid)-nrps8 into the A.keratiniphila cell, so as to obtain the A.keratiniphila cell. The invention also discloses an application of the nrps8 gene of the A. keratiniphila as a gene knockout target of CRISPR / Cas9 (clustered regularly interspaced short palindromic repeats / CRISPR associated protein 9) in the preparation of vancomycin.

The application relates to a kind of nanocomposites, comprising: carrier;Silver;Vancomycin (Van);And hemin chloride (Hemin);Wherein, the silver, vancomycin (Van) and hemin chloride (Hemin) are loaded on carrier;Wherein the nanocomposite releases silver ion, vancomycin and hemin chloride under near infrared light irradiation.The nanocomposite of the application uses nanomaterial as carrier, and can achieve the purpose of high-efficiency sterilization by the loading of silver combined with Van in hollow cavity.At the same time, hemin chloride can realize photo-thermal conversion in cooperation with silver, and effectively remove redundant active oxygen.The successful implementation of the nanocomposite will lay a foundation for constructing efficient and safe antibacterial strategy and provide a new idea for pathogen infection treatment.

The invention discloses a RuY conjugate of a coumarin modified metal ruthenium derivative and a preparation method and application of the RuY conjugate, metal ruthenium in molecules of the RuY conjugate carries positive charges, and compared with traditional small organic molecules, the RuY conjugate has the advantage that the bacterial cell membrane penetrating capacity and the retention effect of the RuY conjugate are enhanced. Researches find that part of coumarin can be combined with a B subunit of DNA gyrase in bacteria, and DNA superhelix is inhibited by blocking ATP enzyme activity. Therefore, the coumarin derivative has potential antibacterial activity. Tests prove that the RuY conjugate disclosed by the invention can effectively inhibit the growth of aeromonas veronii, nocardia and vancomycin-resistant enterococcus faecium, so that the RuY conjugate is used for preparing medicines for preventing and treating diseases caused by the aeromonas veronii, nocardia and vancomycin-resistant enterococcus faecium, and the RuY conjugate disclosed by the invention provides a new direction for the development of novel antibacterial agents.

The invention provides a method for removing pigments in vancomycin hydrochloride, which comprises the following steps: adjusting the pH value of a vancomycin hydrochloride crude product solution containing pigments to be acidic to obtain a pretreatment feed liquid; carrying out first elution on the pretreated material liquid in a decolorizing column filled with decolorizing resin to obtain an eluent; collecting the eluent and concentrating to obtain a decolorized vancomycin hydrochloride concentrated solution; carrying out a precipitation process on the concentrated solution to obtain a decolorized vancomycin product; wherein the decolorizing resin is selected from at least one of non-polar adsorption resin, ion exchange resin and silica gel filler. According to the method, the pigment in the vancomycin hydrochloride fermentation liquor can be efficiently removed, the absorbance A450nm of the obtained decolorized vancomycin product is greatly reduced, the decolorization yield is high, the loss rate is low, and the removal efficiency of the pigment is greatly improved. In addition, the method can realize repeated utilization of the decolorizing resin, and is more practical and environment-friendly.

The invention belongs to the technical field of chemical drugs, and particularly relates to application of a traditional Chinese medicine composition in preparation of drugs for treating recurrent clostridium difficile infection.The traditional Chinese medicine composition is prepared from 10-50 g of fresh ginger, 3-20 g of honey-fried licorice roots, 5-30 g of ginseng, 3-20 g of dried ginger, 3-30 g of scutellaria baicalensis, 3-30 g of pinellia ternate, 3-15 g of coptis chinensis and 10-30 g of Chinese dates. The traditional Chinese medicine composition is excellent in clinical effect, and in sample research on high-risk crowds such as old people and immunosuppression CDI relapse patients, the treatment scheme of the vancomycin combined with the ginger heart-fire purging decoction is remarkably superior to vancomycin single-drug treatment in the aspect of continuous clinical response rate at the main curative effect end point. This benefit is achieved mainly by reducing the recurrence rate of CDI by more than 60%. The combined scheme shows a robust curative effect in key subgroups such as the elderly and immunosuppressive subgroups, is good in safety, does not increase extra adverse event risks, and particularly does not observe renal function impairment.

The invention provides a vancomycin hydrochloride-containing pharmaceutical composition and a preparation method thereof, the pharmaceutical composition is prepared from vancomycin hydrochloride, PEG6000 and DL-alpha-tocopherol, nitrogen is continuously introduced in the preparation process of the pharmaceutical composition, the whole pharmaceutical composition has simple auxiliary materials and only two auxiliary materials, and the prepared pharmaceutical composition has low content of related substances and is suitable for clinical application. The vancomycin hydrochloride hard capsule is simple in preparation method, high in stability and low in cost, DL-alpha-tocopherol is adopted as an auxiliary material, the prepared vancomycin hydrochloride hard capsule reduces degradation and oxidation of vancomycin hydrochloride, the problem that vancomycin hydrochloride is poor in stability is solved, and the whole preparation method is simple, convenient to operate and suitable for industrial large-scale production.

The invention provides Kineococcus G2 and application of the Kineococcus G2 in preparation of a pigment with antioxidant activity, the Kineococcus new strain G2 is CCTCC No. M20242602, the strain is spherical, the size is 1.0 * 1.5 mu m, the optimal growth temperature is 30-37 DEG C, the pH value is 7.0-9.0, and the salt concentration is 1.0%-2.0%. The strain G2 is not sensitive to bacitracin, ciprofloxacin and norfloxacin, and is sensitive to novobiocin, polymyxin, gentamicin, piperacillin, ofloxacin, erythromycin, streptomycin, kanamycin, rifampicin, ampicillin, vancomycin, carbenicillin, chloramphenicol, tetracycline, penicillin, cefoperazone, oxacillin, amoxicillin and neomycin. Pigment generated by fermentation of the G2 strain has good antioxidant activity, and when the concentration is 10 micrograms / mL, the scavenging activity on DPPH is 25.00%, the scavenging activity on hydroxyl radicals is 80.58%, and the iron ion reducing capacity is 1.57, which are all higher than those of contrast beta-carotenoid. The application of the new Kineococcus strain G2 can lay a foundation for the research of antioxidant drugs such as medical treatment and health care product development.

A total synthesis of a new class of vancomycin analogues of reduced synthetic complexity was developed. The synthesis, achieved by the addition of two aryl chloride substituents to provide tetrachlorovancomcyin aglycon (Compound II), tetrachlorovancomcyin (Compound I ), and their derivatives, permitted a streamlined total synthesis of the new class of glycopeptide antibiotics by removing atropisomer stereochemical control and enabled the simultaneous and further activated SNAr macrocyclizations that establish the tricyclic skeleton of Compound I. In addition to the antimicrobial evaluation of tetrachlorovancomycin (Compound I), the preparation of key binding pocket and peripherally-modi fied derivatives, which overcome vancomycin resistance and introduce independent and synergistic mechanisms of action, revealed their exceptional antimicrobial potency and provide the foundation for use of this new class of synthetic glycopeptide analogues. Also disclosed are a pharmaceutical composition containing bactericidal amount of tetrachlorovancomycin, a derivative thereof or a salt of either dissolved or dispersed in a pharmaceutically acceptable diluent.

The invention discloses a fixing material for a medical device implant and a preparation method of the fixing material. The fixing material comprises a degradable polymer base material with a porous structure and a drug sustained-release coating uniformly loaded on the degradable polymer base material, holes in the degradable polymer are uniformly distributed in a staggered array manner, the holes are circular, the aperture of each hole is 0.5-3.0 mm, and the distance between every two adjacent holes is 0.5-3.0 mm; the drug sustained-release coating contains antibiotics; the antibiotics comprise rifampicin, minocycline hydrochloride, vancomycin, tobramycin, gentamicin and the like. The fixing material disclosed by the invention takes the degradable polymer as a base material, and the drug-loading coating containing antibiotics and anti-inflammatory substances is loaded on the surface, so that slow release of antibiotic drugs can be realized, and the fixing material has excellent antibacterial and anti-inflammatory performance and complete absorbability in a biological environment; and the problems of biocompatibility, infection risk and secondary operation removal of the implant for a long time are solved.

The invention discloses a vancomycin hydrochloride solid capsule. The vancomycin hydrochloride solid capsule comprises a capsule shell and a content, the content comprises the following components in percentage by weight: 30%-40% of vancomycin hydrochloride, 5%-20% of Tween 80, 40%-65% of polyethylene glycol 6000 and 0.1%-1% of ascorbyl palmitate. The invention also discloses a preparation method of the vancomycin hydrochloride solid capsule, which comprises the following steps: (1) placing the Tween 80 and the polyethylene glycol 6000 in a container according to the formula ratio, and heating until the Tween 80 and the polyethylene glycol 6000 are molten; (2) adding the crushed vancomycin hydrochloride into molten polyethylene glycol, and uniformly stirring and mixing to obtain a molten mixed solution; and (3) filling a capsule shell with the molten mixed solution to obtain the capsule. The vancomycin hydrochloride capsule for oral administration can be prepared at a lower temperature through combined use of the Tween 80 and the ascorbic acid palmitate, and the problem that the vancomycin hydrochloride and a liquid preparation thereof are poor in stability is solved.

A total synthesis of a new class of vancomycin analogues of reduced synthetic complexity was developed. The synthesis, achieved by the addition of two aryl chloride substituents to provide tetrachlorovancomcyin aglycon (Compound II), tetrachlorovancomcyin (Compound I ), and their derivatives, permitted a streamlined total synthesis of the new class of glycopeptide antibiotics by removing atropisomer stereochemical control and enabled the simultaneous and further activated SNAr macrocyclizations that establish the tricyclic skeleton of Compound I. In addition to the antimicrobial evaluation of tetrachlorovancomycin (Compound I), the preparation of key binding pocket and peripherally-modi fied derivatives, which overcome vancomycin resistance and introduce independent and synergistic mechanisms of action, revealed their exceptional antimicrobial potency and provide the foundation for use of this new class of synthetic glycopeptide analogues. Also disclosed are a pharmaceutical composition containing bactericidal amount of tetrachlorovancomycin, a derivative thereof or a salt of either dissolved or dispersed in a pharmaceutically acceptable diluent.

The present disclosure relates to stable aqueous solutions of vancomycin or its pharmaceutically acceptable salt, that are ready to administer to the patient, and those that can be diluted with a suitable diluent, prior to administration.